Alcoholic Hepatitis clinical trials at UCSF

1 research study open to eligible people

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
open to eligible people ages 18 years and up
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
San Francisco, California and other locations

Last updated: November 2022